| 1 |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2 |
郑荣寿, 陈茹, 韩冰峰. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231.
|
| 3 |
Carbone DP, Hirsch FR, Osarogiagbon RU, et al. The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database[J]. J Thorac Oncol, 2025, 20(10): 1423-1440.
|
| 4 |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51.
|
| 5 |
Jin Y, Chen M, Yu X. Comparison of the 7(th) and proposed 8(th) editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery[J]. Sci Rep, 2016, 6: 33587.
|
| 6 |
Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2017, 12(7): 1109-1121.
|
| 7 |
Zhang Y, Sun Y, Xiang J, et al. A clinicopathologic prediction model for postoperative recurrence in stage Ⅰa non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2014, 148(4): 1193-1199.
|
| 8 |
Kamigaichi A, Tsutani Y, Mimae T, et al. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage ⅠA non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2022, 62:: ezac166.
|
| 9 |
Hattori A, Suzuki K, Takamochi K, et al. Prognostic impact of a ground-glass opacity component in clinical stage ⅠA non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2021, 161(4): 1469-1480.
|
| 10 |
Motono N, Ishikawa M, Iwai S, et al. Risk factors of up-Stage and lymph node metastasis for clinical stage ⅠA3 non-small cell lung cancer[J]. J Thorac Dis, 2025, 17(10): 8613-8622.
|
| 11 |
Li X, Fan F, Yang Z, et al. Ten-Year Follow-Up of Lung Cancer Patients with Resected Stage ⅠA Invasive Non-Small Cell Lung Cancer[J]. Ann Surg Oncol, 2024, 31(9): 5729-5737.
|
| 12 |
Yoon DW, Kim CH, Hwang S, et al. Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage ⅠA lung cancer[J]. Insights Imaging, 2022, 13(1): 103.
|
| 13 |
Yan H, Niimi T, Matsunaga T, et al. Preoperatively predicting survival outcome for clinical stage ⅠA pure-solid non-small cell lung cancer by radiomics-based machine learning[J]. J Thorac Cardiovasc Surg, 2025, 169(1): 254-266.e9.
|
| 14 |
Shimada Y, Kudo Y, Maehara S, et al. Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage ⅠA Lung Cancer[J]. Ann Surg Oncol, 2022, 29(13): 8185-8193.
|
| 15 |
Wang T, She Y, Yang Y, et al. Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage ⅠA Pure-Solid Non-Small Cell Lung Cancer[J]. Radiology, 2022, 302(2): 425-434.
|
| 16 |
Choe J, Kim MY, Yun JK, et al. Sublobar Resection in Stage ⅠA Non-Small Cell Lung Cancer: Role of Preoperative CT Features in Predicting Pathologic Lymphovascular Invasion and Postoperative Recurrence[J]. AJR Am J Roentgenol, 2021, 217(4): 871-881.
|
| 17 |
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification[J]. J Thorac Oncol, 2015, 10(9): 1243-1260.
|
| 18 |
Ikeda T, Kadota K, Yoshida C, et al. The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces and a high risk of recurrence after resection of lung carcinoma[J]. Lung Cancer, 2021, 153: 49-55.
|
| 19 |
Han YB, Kim H, Mino-Kenudson M, et al. Tumor spread through air spaces (STAS): prognostic significance of grading in non-small cell lung cancer[J]. Mod Pathol, 2021, 34(3): 549-561.
|
| 20 |
Lu S, Tan K S, Kadota K, et al. Spread through air spaces (STAS) is an independent predictor of recurrence and lung cancer specific death in squamous cell carcinoma[J]. J Thorac Oncol, 2017, 12(2): 223-234.
|
| 21 |
Maeda R, Yoshida J, Ishii G, et al. Risk factors for tumor recurrence in patients with early-stage (stage Ⅰ and Ⅱ) non-small cell lung cancer[J]. Chest, 2011, 140(6): 1494-1502.
|
| 22 |
Bu J, Zhang P, Li P, et al. The relationship between blood biomarkers and prognosis of pathologic stage ⅠA pure-solid non-small cell lung cancer patients[J]. J Thorac Dis, 2025, 17(5): 2967-2979.
|
| 23 |
Dagher S, Sulaiman A, Bayle-Bleuez S, et al. Spread Through Air Spaces (STAS) Is an Independent Prognostic Factor in Resected Lung Squamous Cell Carcinoma[J]. Cancers (Basel), 2022, 14(9): 2281.
|
| 24 |
Howington JA, Blum MG, Chang AC, et al. Treatment of stage Ⅰ and Ⅱ non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e278S-e313S.
|
| 25 |
Nobel TB, Tan KS, Adusumilli PS, et al. Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage ⅠA Lung Cancer[J]. Ann Thorac Surg, 2024, 118(3): 655-663.
|
| 26 |
Kamigaichi A, Tsutani Y, Kagimoto A, et al. Comparing Segmentectomy and Lobectomy for Clinical Stage ⅠA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm[J]. Clin Lung Cancer, 2020, 21(6): e528-e538.
|
| 27 |
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group[J]. Ann Thorac Surg, 1995, 60(3): 615-622.
|
| 28 |
Hattori A, Matsunaga T, Takamochi K, et al. Importance of Ground Glass Opacity Component in Clinical Stage ⅠA Radiologic Invasive Lung Cancer[J]. Ann Thorac Surg, 2017, 104(1): 313-320.
|
| 29 |
Lin H, Peng Z, Zhou K, et al. Differential efficacy of segmentectomy and wedge resection in sublobar resection compared to lobectomy for solid-dominant stage ⅠA lung cancer: a systematic review and meta-analysis[J]. Int J Surg, 2024, 110(2): 1159-1171.
|
| 30 |
Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial[J]. Lancet, 2022, 399(10335): 1607-1617.
|
| 31 |
Onaitis MW, Furnary AP, Kosinski AS, et al. Equivalent Survival Between Lobectomy and Segmentectomy for Clinical Stage ⅠA Lung Cancer[J]. Ann Thorac Surg, 2020, 110(6): 1882-1891.
|
| 32 |
Altorki NK, Wang X, Kozono D, et al. Lobar or sublobar resection for peripheral stage ⅠA non-small cell lung cancer[J]. N Engl J Med, 2023, 388(6): 489-498.
|
| 33 |
Ortiz BA, Engrav SK, Boland JM, et al. Diagnostic yield of routine frozen section pathology examination of lymph nodes in lung resections for clinical stage ⅠA non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2026, 171(2): 493-499.
|
| 34 |
Wang C, Hu Y, Min B, et al. Sublobar resection is non-inferior to lobectomy in octogenarians and older with stage Ⅰa non-small cell lung cancer[J]. Transl Cancer Res, 2025, 14(5): 2966-2980.
|
| 35 |
Pan H, Zou N, Tian Y, et al. Robotic Versus Thoracoscopic Sub-lobar Resection for Octogenarians with Clinical Stage ⅠA Non-small Cell Lung Cancer: A Propensity Score-Matched Real-World Study[J]. Ann Surg Oncol, 2024, 31(3): 1568-1580.
|
| 36 |
Gu C, Wang R, Pan X, et al. Sublobar resection versus lobectomy in patients aged ≤35 years with stage ⅠA non-small cell lung cancer: a SEER database analysis[J]. J Cancer Res Clin Oncol, 2017, 143(11): 2375-2382.
|
| 37 |
Nakagawa K, Tada H, Akashi A, et al. Randomized study of adjuvant chemotherapy for completely resected p-stage Ⅰ~ⅢA non-small cell lung cancer[J]. Br J Cancer, 2006, 95(7): 817-821.
|
| 38 |
Yamamoto H, Soh J, Okumura N, et al. Randomized phase Ⅱ study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage ⅠA~ⅢA NSCLC[J]. PLoS One, 2023, 18(5): e0285273.
|
| 39 |
Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung[J]. N Engl J Med, 2004, 350(17): 1713-1721.
|
| 40 |
Okumura N, Soh J, Suzuki H, et al. Randomized phase Ⅱ study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage Ⅰ non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301[J]. BMC Cancer, 2021, 21(1): 506.
|
| 41 |
Wakelee HA, Dahlberg SE, Keller SM, et al. Interim report of on-study demographics and toxicity from E1505, a phase Ⅲ randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2011, 29(15): 2121-2127.
|
| 42 |
Tsutani Y, lmai K, ltc H, et al. Adjuvant chemotherapy for high-risk pathological stage Ⅰ non-small cell lung cancer[J]. Ann Thorac Surg, 2022, 113(5): 1608-1616.
|
| 43 |
Lee TH, Kuo CY, Shen YW, et al. Prognostic significance of tumor spread through air spaces and lymphovascular invasion in stage I non-small cell lung cancer[J]. World J Surg Oncol, 2025, 23(1): 325.
|
| 44 |
Ak N, Ozkan B, Yenigun MB, et al. The role of adjuvant chemotherapy in resected stage Ⅰ non-small cell lung cancer: A Turkish Oncology Group Study[J]. J BUON, 2021, 26(3): 819-829.
|
| 45 |
Imaizumi M, Abe T, Kunishima K, et al. A Randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer[J]. Eur J Cancer, 1995, 21(1): 69-77.
|
| 46 |
Neal JW, Costa DB, Muzikansky A, et al. Randomized Phase Ⅱ Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage Ⅰ~Ⅲ EGFR-Mutant Non-Small-Cell Lung Cancer[J]. JCO Precis Oncol, 2021, 5: 325-332.
|
| 47 |
Coleman MH, Bueno R. Role of adjuvant chemotherapy in NSCLC (stages I to III)[J]. Surg Oncol Clin N Am, 2011, 20(4): 757-767.
|
| 48 |
Pisters KM. The role of chemotherapy in early-stage (stage Ⅰ and Ⅱ) resectable non-small cell lung cancer[J]. Semin Radiat Oncol, 2000, 10(4): 274-279.
|
| 49 |
Ma X, He W, Chen C, et al. A CT-based deep learning model for preoperative prediction of spread through air spaces in clinical stage Ⅰ lung adenocarcinoma[J]. Front Oncol, 2024, 14: 1482965.
|
| 50 |
Chen LW, Yang SM, Chuang CC, et al. Solid Attenuation Components Attention Deep Learning Model to Predict Micropapillary and Solid Patterns in Lung Adenocarcinomas on Computed Tomography[J]. Ann Surg Oncol, 2022, 29(12): 7473-7482.
|
| 51 |
Chuang CH, Liu YW, Lai WA, et al. Impact of Spread Through Air Spaces (STAS) on Recurrence and Surgical Trends in Stage Ⅰ Non-Small Cell Lung Cancer: A Real-World Cohort Study[J]. Kaohsiung J Med Sci, 2025, 41(10): e70061.
|